The world of microbial solutions is getting lively. Not to be outdone by Symbiota, which just announced a $7.5M Series A backed by Flagship Ventures, AgBiome disclosed the participation of Syngenta, Monsanto, and Novozymes alongside Polaris Partners, ARCH Venture Partners, Harris & Harris and Innotech Advisors in a $17.5M Series A which closed last year.
AgBiome uses a proprietary platform to collect, isolate, analyze, and test microbes for use in agriculture as biological products and as sources of trait genes.
“This dream syndicate came together in a unique way to move the company forward,” said Scott Uknes, Co-CEO of AgBiome. “This sort of combined investment is unprecedented to our knowledge, and is both a testament to our vision and team and a catalyst for innovation in the space.”
“As a venture investor in this promising company, it is gratifying to see that each of these well-positioned investors sees promise in AgBiome,” said Amir Nashat, Managing Partner at Polaris Partners. “AgBiome has developed an outstanding platform and we look forward to working with these and other investors as we advance to the next level of development.”
The strategic investors expressed their optimism for the future of AgBiome. Katrin Burt of Syngenta Ventures commented, “at Syngenta Ventures, we look for companies with great teams and a business focus that can make a step change in dramatically improving agriculture. AgBiome is exceptional on both fronts, but it also has a unique business model and structure that positions the company well for success.”
Have news or tips? Email [email protected]
Sponsored
Sponsored post: The innovator’s dilemma: why agbioscience innovation must focus on the farmer first